Overview
- Peptide (C)EDEFRYRMYQTQVSD, corresponding to amino acid residues 635 - 649 of mouse PTGFRN (Accession Q9WV91). Extracellular, N-terminus.
PTGFRN (extracellular) Blocking Peptide (#BLP-NR212)
- Western blot analysis of rat brain membranes (lanes 1 and 3) and mouse brain membranes (lanes 2 and 4):1-2. Anti-PTGFRN (extracellular) Antibody (#ANR-212), (1:400).
3-4. Anti-PTGFRN (extracellular) Antibody, preincubated with PTGFRN (extracellular) Blocking Peptide (BLP-NR212). - Western blot analysis of human pancreatic carcinoma PANC-1 cell line lysate (lanes 1 and 4), human breast adenocarcinoma MCF-7 cell line (lanes 2 and 5) and human U-87 MG glioblastoma cell line (lanes 3 and 6):1-3. Anti-PTGFRN (extracellular) Antibody (#ANR-212), (1:400).
4-6. Anti-PTGFRN (extracellular) Antibody, preincubated with PTGFRN (extracellular) Blocking Peptide (BLP-NR212).
- Expression of PTGFRN in mouse hypothalamus:Immunohistochemical staining of perfusion-fixed frozen mouse brain sections with Anti-PTGFRN (extracellular) Antibody (#ANR-212), (1:300), followed by goat anti-rabbit-AlexaFluor-488. A. PTGFRN immunoreactivity (green) appears in cells of ventromedial hypothalamus (arrows). B. Pre-incubation of the antibody with PTGFRN (extracellular) Blocking Peptide (BLP-NR212), suppressed staining. Cell nuclei are stained with DAPI (blue). 3rd V = 3rd ventricle.
- Expression of PTGFRN in rat hippocampal dentate gyrus:Immunohistochemical staining of perfusion-fixed frozen rat brain sections with Anti-PTGFRN (extracellular) Antibody (#ANR-212), (1:300), followed by goat anti-rabbit-AlexaFluor-488. A. PTGFRN immunoreactivity (green) appears in cells of the sub-granular layer (GL). B. Pre-incubation of the antibody with PTGFRN (extracellular) Blocking Peptide (BLP-NR212), suppressed staining. Cell nuclei are stained with DAPI (blue).
- Cell surface detection of PTGFRN by indirect flow cytometry in live intact human Jurkat T-cell leukemia cell line:___ Cells.
___ Cells + goat-anti-rabbit-APC.
___ Cells + Anti-PTGFRN (extracellular) Antibody (#ANR-212), (2.5μg) + goat-anti-rabbit-APC.
- Mala et al. (2022) BMC Cancer, 22, 642.
- Aguila et al. (2019) Cancer Lett., 462, 33–42.
- Muraoka et al. (2020) Cells, 9, 1959.
- Marquez et al. (2021) PLoS One, 16, e0246197.
The Prostaglandin F2 Receptor Negative Regulator (PTGFRN), also known as EWI-F and CD9P-1, is a member of the immunoglobulin (Ig) superfamily. PTGFRN is a type I single-pass transmembrane protein and part of the cell adhesion molecule (CAM) family, which plays essential roles in cell-cell and cell-matrix interactions1,2.
CAMs, including PTGFRN, are characterized by extracellular Ig-like domains and contribute to cellular adhesion, migration, and signaling. PTGFRN interacts with tetraspanins (CD9, CD81), integrins, and ERM proteins, functioning as a scaffold in tetraspanin-enriched microdomains (TEMs)3. These interactions enable its role in tumor progression, metastasis, and angiogenesis by regulating PI3K/AKT and mTOR signaling pathways1,2.
PTGFRN is highly expressed in glioblastoma (GBM) and several cancers, with significantly elevated levels in tumor tissues compared to normal tissues1,2,3. It is implicated in tumor proliferation, migration, and radiation resistance. In neurodegenerative disorders, PTGFRN correlates with Alzheimer’s disease progression via its role in extracellular vesicles (EVs) associated with amyloid plaques3.
PTGFRN’s association with poor prognosis in cancers and its involvement in neurodegeneration highlight its potential as a therapeutic target. Immunodetection of PTGFRN can benefit research areas in oncology, neurobiology, and regenerative medicine1,2,4.
Application key:
Species reactivity key:
Anti-PTGFRN (extracellular) Antibody (#ANR-212) is a highly specific antibody directed against an extracellular epitope of the mouse protein. The antibody can be used in western blot, immunohistochemistry and flow cytometry applications. It has been designed to recognize PTGFRN from mouse, rat and human samples.